CN115137072A - 一种增强免疫的组合物及其制备方法 - Google Patents
一种增强免疫的组合物及其制备方法 Download PDFInfo
- Publication number
- CN115137072A CN115137072A CN202210589588.3A CN202210589588A CN115137072A CN 115137072 A CN115137072 A CN 115137072A CN 202210589588 A CN202210589588 A CN 202210589588A CN 115137072 A CN115137072 A CN 115137072A
- Authority
- CN
- China
- Prior art keywords
- parts
- extract
- composition
- american ginseng
- health food
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 239000000203 mixture Substances 0.000 title claims abstract description 25
- 230000036039 immunity Effects 0.000 title claims abstract description 14
- 238000002360 preparation method Methods 0.000 title claims abstract description 14
- 230000002708 enhancing effect Effects 0.000 title claims abstract description 11
- 240000005373 Panax quinquefolius Species 0.000 claims abstract description 23
- 235000003140 Panax quinquefolius Nutrition 0.000 claims abstract description 23
- TZCPCKNHXULUIY-RGULYWFUSA-N 1,2-distearoyl-sn-glycero-3-phosphoserine Chemical compound CCCCCCCCCCCCCCCCCC(=O)OC[C@H](COP(O)(=O)OC[C@H](N)C(O)=O)OC(=O)CCCCCCCCCCCCCCCCC TZCPCKNHXULUIY-RGULYWFUSA-N 0.000 claims abstract description 18
- ZWZWYGMENQVNFU-UHFFFAOYSA-N Glycerophosphorylserin Natural products OC(=O)C(N)COP(O)(=O)OCC(O)CO ZWZWYGMENQVNFU-UHFFFAOYSA-N 0.000 claims abstract description 18
- 244000042430 Rhodiola rosea Species 0.000 claims abstract description 16
- 235000003713 Rhodiola rosea Nutrition 0.000 claims abstract description 16
- FZAQROFXYZPAKI-UHFFFAOYSA-N anthracene-2-sulfonyl chloride Chemical compound C1=CC=CC2=CC3=CC(S(=O)(=O)Cl)=CC=C3C=C21 FZAQROFXYZPAKI-UHFFFAOYSA-N 0.000 claims abstract description 13
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 claims abstract description 12
- 239000000463 material Substances 0.000 claims abstract description 9
- 235000019359 magnesium stearate Nutrition 0.000 claims abstract description 6
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 19
- 239000000843 powder Substances 0.000 claims description 18
- 235000013402 health food Nutrition 0.000 claims description 15
- 239000002994 raw material Substances 0.000 claims description 15
- 239000000706 filtrate Substances 0.000 claims description 11
- 239000008187 granular material Substances 0.000 claims description 8
- 241001165494 Rhodiola Species 0.000 claims description 7
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 claims description 6
- 238000000034 method Methods 0.000 claims description 6
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 claims description 5
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 claims description 5
- 229930195725 Mannitol Natural products 0.000 claims description 5
- 229920000168 Microcrystalline cellulose Polymers 0.000 claims description 5
- 229920002472 Starch Polymers 0.000 claims description 5
- 238000001035 drying Methods 0.000 claims description 5
- 239000008101 lactose Substances 0.000 claims description 5
- 239000000594 mannitol Substances 0.000 claims description 5
- 235000010355 mannitol Nutrition 0.000 claims description 5
- 235000019813 microcrystalline cellulose Nutrition 0.000 claims description 5
- 239000008108 microcrystalline cellulose Substances 0.000 claims description 5
- 229940016286 microcrystalline cellulose Drugs 0.000 claims description 5
- 235000013809 polyvinylpolypyrrolidone Nutrition 0.000 claims description 5
- 229920000523 polyvinylpolypyrrolidone Polymers 0.000 claims description 5
- 239000008107 starch Substances 0.000 claims description 5
- 235000019698 starch Nutrition 0.000 claims description 5
- 239000003826 tablet Substances 0.000 claims description 5
- WHNWPMSKXPGLAX-UHFFFAOYSA-N N-Vinyl-2-pyrrolidone Chemical compound C=CN1CCCC1=O WHNWPMSKXPGLAX-UHFFFAOYSA-N 0.000 claims description 4
- 229960000913 crospovidone Drugs 0.000 claims description 4
- 238000001914 filtration Methods 0.000 claims description 4
- 239000000741 silica gel Substances 0.000 claims description 4
- 229910002027 silica gel Inorganic materials 0.000 claims description 4
- 239000002552 dosage form Substances 0.000 claims description 3
- 238000001694 spray drying Methods 0.000 claims description 3
- 239000002775 capsule Substances 0.000 claims description 2
- 239000007788 liquid Substances 0.000 claims description 2
- 239000006187 pill Substances 0.000 claims description 2
- 239000002671 adjuvant Substances 0.000 claims 1
- 239000002417 nutraceutical Substances 0.000 claims 1
- 235000021436 nutraceutical agent Nutrition 0.000 claims 1
- 230000000694 effects Effects 0.000 abstract description 6
- 235000013305 food Nutrition 0.000 abstract description 4
- 238000010521 absorption reaction Methods 0.000 abstract description 3
- 230000006870 function Effects 0.000 description 7
- 239000000047 product Substances 0.000 description 7
- BAWFJGJZGIEFAR-NNYOXOHSSA-N NAD zwitterion Chemical compound NC(=O)C1=CC=C[N+]([C@H]2[C@@H]([C@H](O)[C@@H](COP([O-])(=O)OP(O)(=O)OC[C@@H]3[C@H]([C@@H](O)[C@@H](O3)N3C4=NC=NC(N)=C4N=C3)O)O2)O)=C1 BAWFJGJZGIEFAR-NNYOXOHSSA-N 0.000 description 6
- 239000012528 membrane Substances 0.000 description 6
- 238000012360 testing method Methods 0.000 description 6
- 210000000170 cell membrane Anatomy 0.000 description 5
- 238000002156 mixing Methods 0.000 description 5
- 229950006238 nadide Drugs 0.000 description 5
- 210000004556 brain Anatomy 0.000 description 4
- 201000010099 disease Diseases 0.000 description 4
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 4
- 210000003743 erythrocyte Anatomy 0.000 description 4
- 238000011156 evaluation Methods 0.000 description 4
- 229930027945 nicotinamide-adenine dinucleotide Natural products 0.000 description 4
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 3
- 241000699666 Mus <mouse, genus> Species 0.000 description 3
- 238000002474 experimental method Methods 0.000 description 3
- 210000000987 immune system Anatomy 0.000 description 3
- 238000005259 measurement Methods 0.000 description 3
- 239000000126 substance Substances 0.000 description 3
- JZNWSCPGTDBMEW-UHFFFAOYSA-N Glycerophosphorylethanolamin Natural products NCCOP(O)(=O)OCC(O)CO JZNWSCPGTDBMEW-UHFFFAOYSA-N 0.000 description 2
- 241000699670 Mus sp. Species 0.000 description 2
- DFPAKSUCGFBDDF-UHFFFAOYSA-N Nicotinamide Chemical compound NC(=O)C1=CC=CN=C1 DFPAKSUCGFBDDF-UHFFFAOYSA-N 0.000 description 2
- 241000700159 Rattus Species 0.000 description 2
- 230000002159 abnormal effect Effects 0.000 description 2
- 210000004369 blood Anatomy 0.000 description 2
- 239000008280 blood Substances 0.000 description 2
- 210000002149 gonad Anatomy 0.000 description 2
- 230000036541 health Effects 0.000 description 2
- 238000007689 inspection Methods 0.000 description 2
- 210000003734 kidney Anatomy 0.000 description 2
- 210000004185 liver Anatomy 0.000 description 2
- 231100000682 maximum tolerated dose Toxicity 0.000 description 2
- 230000004060 metabolic process Effects 0.000 description 2
- 231100000252 nontoxic Toxicity 0.000 description 2
- 230000003000 nontoxic effect Effects 0.000 description 2
- WTJKGGKOPKCXLL-RRHRGVEJSA-N phosphatidylcholine Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCCCCCCC=CCCCCCCCC WTJKGGKOPKCXLL-RRHRGVEJSA-N 0.000 description 2
- 150000008104 phosphatidylethanolamines Chemical class 0.000 description 2
- -1 serine phospholipids Chemical class 0.000 description 2
- 238000007873 sieving Methods 0.000 description 2
- 210000000813 small intestine Anatomy 0.000 description 2
- 239000007779 soft material Substances 0.000 description 2
- 210000000952 spleen Anatomy 0.000 description 2
- 210000002784 stomach Anatomy 0.000 description 2
- GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 1
- 238000010953 Ames test Methods 0.000 description 1
- 231100000039 Ames test Toxicity 0.000 description 1
- 241000894006 Bacteria Species 0.000 description 1
- 206010006458 Bronchitis chronic Diseases 0.000 description 1
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 1
- 208000024172 Cardiovascular disease Diseases 0.000 description 1
- 208000017667 Chronic Disease Diseases 0.000 description 1
- 206010008909 Chronic Hepatitis Diseases 0.000 description 1
- 241000196324 Embryophyta Species 0.000 description 1
- 102000004190 Enzymes Human genes 0.000 description 1
- 108090000790 Enzymes Proteins 0.000 description 1
- 208000005577 Gastroenteritis Diseases 0.000 description 1
- 206010018910 Haemolysis Diseases 0.000 description 1
- 241000282412 Homo Species 0.000 description 1
- 238000012449 Kunming mouse Methods 0.000 description 1
- 102000003855 L-lactate dehydrogenase Human genes 0.000 description 1
- 108700023483 L-lactate dehydrogenases Proteins 0.000 description 1
- 241001465754 Metazoa Species 0.000 description 1
- 206010028980 Neoplasm Diseases 0.000 description 1
- 206010067482 No adverse event Diseases 0.000 description 1
- 201000007100 Pharyngitis Diseases 0.000 description 1
- 102100027378 Prothrombin Human genes 0.000 description 1
- 108010094028 Prothrombin Proteins 0.000 description 1
- 206010039085 Rhinitis allergic Diseases 0.000 description 1
- MTCFGRXMJLQNBG-UHFFFAOYSA-N Serine Natural products OCC(N)C(O)=O MTCFGRXMJLQNBG-UHFFFAOYSA-N 0.000 description 1
- 206010050208 Teratospermia Diseases 0.000 description 1
- 208000002312 Teratozoospermia Diseases 0.000 description 1
- 241000700605 Viruses Species 0.000 description 1
- 230000003213 activating effect Effects 0.000 description 1
- 231100000460 acute oral toxicity Toxicity 0.000 description 1
- 231100000403 acute toxicity Toxicity 0.000 description 1
- 230000007059 acute toxicity Effects 0.000 description 1
- 238000011047 acute toxicity test Methods 0.000 description 1
- 239000000853 adhesive Substances 0.000 description 1
- 230000001070 adhesive effect Effects 0.000 description 1
- 201000010105 allergic rhinitis Diseases 0.000 description 1
- 239000003674 animal food additive Substances 0.000 description 1
- 230000002929 anti-fatigue Effects 0.000 description 1
- 210000000628 antibody-producing cell Anatomy 0.000 description 1
- 208000006673 asthma Diseases 0.000 description 1
- 230000001363 autoimmune Effects 0.000 description 1
- 230000006399 behavior Effects 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 230000000975 bioactive effect Effects 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 230000037396 body weight Effects 0.000 description 1
- 210000002798 bone marrow cell Anatomy 0.000 description 1
- 206010006451 bronchitis Diseases 0.000 description 1
- 201000011510 cancer Diseases 0.000 description 1
- 229910052799 carbon Inorganic materials 0.000 description 1
- 210000004027 cell Anatomy 0.000 description 1
- 230000003833 cell viability Effects 0.000 description 1
- 230000001413 cellular effect Effects 0.000 description 1
- 238000006243 chemical reaction Methods 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- 208000007451 chronic bronchitis Diseases 0.000 description 1
- 230000000052 comparative effect Effects 0.000 description 1
- 239000007891 compressed tablet Substances 0.000 description 1
- 230000001276 controlling effect Effects 0.000 description 1
- 238000001514 detection method Methods 0.000 description 1
- 206010012601 diabetes mellitus Diseases 0.000 description 1
- 238000004090 dissolution Methods 0.000 description 1
- 238000000605 extraction Methods 0.000 description 1
- 239000007888 film coating Substances 0.000 description 1
- 238000009501 film coating Methods 0.000 description 1
- 235000012055 fruits and vegetables Nutrition 0.000 description 1
- 231100000025 genetic toxicology Toxicity 0.000 description 1
- 230000001738 genotoxic effect Effects 0.000 description 1
- 150000002327 glycerophospholipids Chemical class 0.000 description 1
- 238000000227 grinding Methods 0.000 description 1
- 210000002216 heart Anatomy 0.000 description 1
- 208000006454 hepatitis Diseases 0.000 description 1
- 238000001727 in vivo Methods 0.000 description 1
- 208000015181 infectious disease Diseases 0.000 description 1
- 238000004898 kneading Methods 0.000 description 1
- 210000004698 lymphocyte Anatomy 0.000 description 1
- 238000006241 metabolic reaction Methods 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 210000000822 natural killer cell Anatomy 0.000 description 1
- 210000000653 nervous system Anatomy 0.000 description 1
- 229960003966 nicotinamide Drugs 0.000 description 1
- 235000005152 nicotinamide Nutrition 0.000 description 1
- 239000011570 nicotinamide Substances 0.000 description 1
- 229940101270 nicotinamide adenine dinucleotide (nad) Drugs 0.000 description 1
- 239000002773 nucleotide Substances 0.000 description 1
- 125000003729 nucleotide group Chemical group 0.000 description 1
- 210000000056 organ Anatomy 0.000 description 1
- 231100000915 pathological change Toxicity 0.000 description 1
- 230000036285 pathological change Effects 0.000 description 1
- 230000035699 permeability Effects 0.000 description 1
- 150000003904 phospholipids Chemical class 0.000 description 1
- 239000001253 polyvinylpolypyrrolidone Substances 0.000 description 1
- 239000002243 precursor Substances 0.000 description 1
- 229940039716 prothrombin Drugs 0.000 description 1
- 230000001105 regulatory effect Effects 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 239000000377 silicon dioxide Substances 0.000 description 1
- 230000003393 splenic effect Effects 0.000 description 1
- 229910001220 stainless steel Inorganic materials 0.000 description 1
- 239000010935 stainless steel Substances 0.000 description 1
- 238000003756 stirring Methods 0.000 description 1
- 238000003786 synthesis reaction Methods 0.000 description 1
- 231100000820 toxicity test Toxicity 0.000 description 1
- 238000009602 toxicology test Methods 0.000 description 1
- 230000009466 transformation Effects 0.000 description 1
- 210000002700 urine Anatomy 0.000 description 1
- 210000001835 viscera Anatomy 0.000 description 1
- 230000009278 visceral effect Effects 0.000 description 1
- 239000012856 weighed raw material Substances 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/13—Nucleic acids or derivatives thereof
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/105—Plant extracts, their artificial duplicates or their derivatives
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/115—Fatty acids or derivatives thereof; Fats or oils
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/66—Phosphorus compounds
- A61K31/683—Diesters of a phosphorus acid with two hydroxy compounds, e.g. phosphatidylinositols
- A61K31/685—Diesters of a phosphorus acid with two hydroxy compounds, e.g. phosphatidylinositols one of the hydroxy compounds having nitrogen atoms, e.g. phosphatidylserine, lecithin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
- A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
- A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/25—Araliaceae (Ginseng family), e.g. ivy, aralia, schefflera or tetrapanax
- A61K36/258—Panax (ginseng)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/41—Crassulaceae (Stonecrop family)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/04—Immunostimulants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P39/00—General protective or antinoxious agents
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2002/00—Food compositions, function of food ingredients or processes for food or foodstuffs
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Natural Medicines & Medicinal Plants (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Mycology (AREA)
- Epidemiology (AREA)
- Polymers & Plastics (AREA)
- Botany (AREA)
- Food Science & Technology (AREA)
- Immunology (AREA)
- Nutrition Science (AREA)
- Microbiology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Alternative & Traditional Medicine (AREA)
- Medical Informatics (AREA)
- Molecular Biology (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Biotechnology (AREA)
- General Chemical & Material Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biochemistry (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Toxicology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
本发明公开了一种增强免疫的组合物，包括β‑烟酰胺单核苷酸、磷脂酰丝氨酸、红景天提取物及西洋参提取物，还可包括硬脂酸镁等食品学可接受辅料，还公开了其制备方法。本发明所述产品入口即溶，通过舌下吸收，吸收快、效果好，不仅可以改善体质，缓解疲劳，同时可以舒缓压力，增强人体免疫力。
Description
技术领域
本发明涉及一种食用组合物，尤其涉及一种能够增强免疫的组合物，及该组合物的制备方法。
背景技术
人体免疫力是人体防御疾病的能力，它是通过人体的免疫系统功能来实现的。正常的免疫系统是捍卫人体健康的盾牌，它能维持机体代谢的内在环境处于稳定状态。一旦免疫系统异常，极易招致细菌，病毒等感染，最直接的表现就是容易生病。当今医学研究表明，威胁人类健康的许多疾病都与人体的免疫力有密切的关系。慢性支气管炎、哮喘、慢性咽炎、过敏性鼻炎、慢性肠胃炎、慢性肝炎、糖尿病等慢性疾病，甚至一些可怕的疾病如癌症、心血管疾病等，都与免疫相关。目前，人类生命的头号大敌“亚健康”产生的最主要原因也是自身免疫功能低下引起的。
发明内容
有鉴于此，本发明提供了一种能够增强免疫的组合物，该组合物的部分成分从植物中提取，具有抗疲劳、增强免疫力的作用。
本发明采取的技术方案如下：
1.一种组合物，以重量份计，由如下原料组成：
β-烟酰胺单核苷酸500-1000份，磷脂酰丝氨酸50-200份，红景天提取物100-400份，西洋参提取物100-355份；其中，
红景天提取物、西洋参提取物通过粉碎，水提取，过滤，减压浓缩，干燥获得。
NMN(Nicotinamide mononucleotide)：全称“β-烟酰胺单核苷酸”，是一种自然存在的生物活性核苷酸。NMN有2种不规则存在形式，α和β；β异构体是NMN的活性形式。NMN是人体内固有的物质，也富含在一些水果和蔬菜中。在人体中NMN是NAD+最直接的前体，其功能是通过NAD+体现。NAD+又叫辅酶Ⅰ，全称烟酰胺腺嘌呤二核苷酸，存在每一个细胞中参与上千项反应。在多种细胞代谢反应中，烟酰胺腺嘌呤二核苷酸(NAD+)分子都扮演着重要角色，是细胞保持活力的重要支撑。
磷脂酰丝氨酸(phosphatidylserine，PS)又称丝氨酸磷脂，二酰甘油酰磷酸丝氨酸，简称PS，是一类普遍存在的磷脂，通常位于细胞膜的内层，磷酯化合物中的磷酸甘油酯类，是细胞膜组分之一，与一系列的膜功能有关。尤其在人体的神经系统，是大脑的细胞膜的重要组成成分之一，同时对大脑的各种功能起到重要的调节作用，如它能影响着细胞膜的流动性、通透性，并且能激活多种酶类的代谢和合成。如人红细胞膜上就有磷脂酰胆碱(占19％)、鞘磷脂(占8％)、磷脂酰乙醇胺(占16％)和磷脂酰丝氨酸(占10％)。并且只有磷脂酰丝氨酸在细胞膜上具有净负电荷，有助于膜的不对称性。还能活化已损伤表面凝血酶原，并与磷脂酰胆碱、磷脂酰乙醇胺在体内可互相转化。磷脂酰丝氨酸可以起到为脑部供血的作用，能够起到较好的改善记忆力的作用，可以较好地提高大脑的机能。
进一步，以重量份计，由如下原料组成：
β-烟酰胺单核苷酸650份，磷脂酰丝氨酸150份，红景天提取物220份，西洋参提取物155份。
进一步，所述红景天提取物制备方法包括：将红景天制成粉末后，按原料与水重量比1:8的比例混合，水温20℃-50℃条件萃取，过滤得滤液，于50～80℃、-0.06MPa～-0.08MPa下减压浓缩，真空干燥至水分不高于5％。
进一步，所述西洋参提取物的制备方法包括：将西洋参制成粉末后，水提取两次，按重量计，第一次按原料与水重量比1：8的比例提取2小时；第二次按原料与水重量比1:7的比例提取1小时；过滤，合并滤液，于50～80℃、-0.06MPa～-0.08MPa条件下减压浓缩，175～185℃条件下喷雾干燥获得。
本发明还提供了上述组合物在制备具有增强免疫力的保健食品中的应用。
本发明还提供了一种具有增强免疫功效的保健食品，包括上述组合物和食品学上可接受的辅料。
进一步，所述保健食品的剂型为片剂、胶囊剂、粉剂、颗粒剂、丸剂或口服液。
进一步，所述保健食品的剂型为片剂，以重量份计，其原辅料包括：β-烟酰胺单核苷酸500-1000份，磷脂酰丝氨酸50-200份，红景天提取物100-400份，西洋参提取物100-355份，淀粉100-300份、甘露醇50-200份、微粉硅胶40-80份、交联聚维酮80-140份、乳糖100-250份、微晶纤维素100-300份、硬脂酸镁10-30份。
进一步，所述保健食品的剂型为片剂，以重量份计，其原辅料包括：β-烟酰胺单核苷酸650份，磷脂酰丝氨酸150份，红景天提取物220份，西洋参提取物155份，淀粉200份、甘露醇100份、微粉硅胶55份、交联聚维酮100份、乳糖150份、微晶纤维素200份、硬脂酸镁20份。
本发明还提供了上述保健食品的制备方法，将组合物和食品学上可接受的辅料混合，然后进行剂型的制备。
采用本发明的有益效果在于：
本发明所述产品具有抗疲劳、增强免疫力的功效，并且本发明产品制成的各种剂型，具有入口即溶，通过舌下吸收，吸收快、效果好的特点。
具体实施方式
实施例1
一种组合物，以重量份计，由如下原料组成：
β-烟酰胺单核苷酸650g，磷脂酰丝氨酸150g，红景天提取物220g，西洋参提取物155g。
其中，
红景天提取物制备方法如下：
将红景天研制成粉末，按红景天粉末与水重量比1：8，水温在20℃-50℃进行萃取，萃取进行2-4次，每次10-60分钟，将几次萃取后过滤出的滤液合并，将滤液置于浓缩罐中于50～80℃、-0.06MPa～-0.08MPa下减压浓缩至相对密度为1.20左右的浸膏，175～185℃，-0.08MPa～-0.1MPa条件下真空干燥获得。
西洋参提取物制备方法如下：
西洋参粉碎成粉末，按西洋参粉末与水重量比1:8先提取2小时，过滤，再以1:7的比例用水提取1小时，合并两次的滤液，将滤液置于浓缩罐中于50～80℃、-0.06MPa～-0.08MPa条件下减压浓缩至相对密度为1.20左右的浸膏，175～185℃喷雾干燥获得(水分含量5.5％以下)。
实施例2
一种组合物，以重量份计，由如下原料组成：
β-烟酰胺单核苷酸500g，磷脂酰丝氨酸50g，红景天提取物100g，西洋参提取物100g。
其中，红景天提取物和西洋参提取物的制备方法参见实施例1。
实施例3
一种组合物，以重量份计，由如下原料组成：
β-烟酰胺单核苷酸1000g，磷脂酰丝氨酸200g，红景天提取物400g，西洋参提取物355g。
其中，红景天提取物和西洋参提取物的制备方法参见实施例1。
实施例4
按照湿法制粒方式制备，具体操作如下：
(1)所有组分先过30目筛，然后按实施例1-3任一种组合物配方准确称取各原料；
(2)将已称好的各原料按等量递增法混合，于高效湿法制粒机中混合5分钟至混合均匀，用体积分数75％乙醇做粘合剂制软材，边加入边搅拌，直至软材“握之成团，捏之既散”，后用摇摆式颗粒机过14目筛制粒；
(3)将湿颗粒置不锈钢盘中，厚度不能超过2厘米，置热风循环烘箱中(60～70℃)干燥，在干燥过程要求翻动两次，水分控制在5％以下；
(4)干燥后的颗粒用摇摆式颗粒机过14目筛整粒；
(5)加入配方量甘露醇、淀粉、乳糖、硬脂酸镁、交联聚维酮、微晶纤维素和微粉硅胶，混合均匀，压片，片重0.3g；
(6)压好的片用薄膜包衣剂包衣。
对安全性评价试验材料的分析评价
本品按照《保健食品检验与评价技术规范》(2003年版)进行安全性毒理学试验，结果如下：
1.经口急性毒性试验结果：对昆明种雌、雄小鼠的最大耐受量(MTD)均大于20.0g/kg BW(相当于人日推荐量750倍)，在观察期间，受试的雌雄小鼠均未出现不良反应和死亡，根据急性毒性分级，表明本品属无毒级。
2.三项遗传毒性试验结果：Ames试验、小鼠骨髓细胞微核试验、小鼠精子畸形试验结果均为阴性。
3.30天喂养试验结果：以0.67g/kg BW、1.34g/kg BW、2.67g/kg BW剂量的本产品给SD大鼠喂食30天，结果表明，大鼠一般生理体征、行为、大小便、皮毛等均无异常，体重和食物利用率指标正常，血液学指标正常，血液生化学指标在参考值范围内，脏器重量、脏/体比值指标正常，心、肝、肾、胃及小肠、脾和性腺等器官的大体检查和肝、肾、胃及小肠、脾和性腺的组织病理学检查，未见与受试物有关的病理改变。
根据《保健食品检验与评价技术规范》(2003年版)判定标准，认为本发明所述产品安全无毒。
动物实验
ConA诱导的小鼠脾淋巴细胞转化实验(MTT法)，抗体生成细胞检测(Jerne改良玻片法)，半数溶血值(HC50)测定，小鼠碳廓清实验、NK细胞活性测定(乳酸脱氢酶测定法)均成阳性，说明受试样品具有增强免疫的功能。
对所公开的实施例的上述说明，使本领域专业技术人员能够实现或使用本发明。对这些实施例的多种修改对本领域的专业技术人员来说将是显而易见的，本文中所定义的一般原理可以在不脱离本发明的精神或范围的情况下，在其它实施例中实现。因此，本发明将不会被限制于本文所示的这些实施例、对比实施例，而是包括符合本文所公开的原理和新颖特点相一致的最宽的范围。
Claims (10)
1.一种组合物，其特征在于，以重量份计，由如下原料组成：
β-烟酰胺单核苷酸500-1000份，磷脂酰丝氨酸50-200份，红景天提取物100-400份，西洋参提取物100-355份；其中，
红景天提取物、西洋参提取物通过粉碎，水提取，过滤，减压浓缩，干燥获得。
2.根据权利要求1所述的组合物，其特征在于，以重量份计，由如下原料组成：
β-烟酰胺单核苷酸650份，磷脂酰丝氨酸150份，红景天提取物220份，西洋参提取物155份。
3.根据权利要求1所述的组合物，其特征在于，所述红景天提取物制备方法包括：将红景天制成粉末后，按原料与水重量比1:8的比例混合，水温20℃-50℃条件萃取，过滤得滤液，于50～80℃、-0.06MPa～-0.08MPa下减压浓缩，真空干燥至水分不高于5％。
4.根据权利要求1所述的组合物，其特征在于，所述西洋参提取物的制备方法包括：将西洋参制成粉末后，水提取两次，按重量计，第一次按原料与水重量比1：8的比例提取2小时；第二次按原料与水重量比1:7的比例提取1小时；过滤，合并滤液，于50～80℃、-0.06MPa～-0.08MPa条件下减压浓缩，175～185℃条件下喷雾干燥获得。
5.权利要求1～4任一项所述组合物在制备具有增强免疫力的保健食品中的应用。
6.一种具有增强免疫功效的保健食品，其特征在于，包括权利要求1至4中任一项组合物和食品学上可接受的辅料。
7.根据权利要求6所述的保健食品，其特征在于，所述保健食品的剂型为片剂、胶囊剂、粉剂、颗粒剂、丸剂或口服液。
8.根据权利要求7所述的保健食品，其特征在于，所述保健食品的剂型为片剂，以重量份计，其原辅料包括：β-烟酰胺单核苷酸500-1000份，磷脂酰丝氨酸50-200份，红景天提取物100-400份，西洋参提取物100-355份，淀粉100-300份、甘露醇50-200份、微粉硅胶40-80份、交联聚维酮80-140份、乳糖100-250份、微晶纤维素100-300份、硬脂酸镁10-30份。
9.根据权利要求7所述的保健食品，其特征在于，所述保健食品的剂型为片剂，以重量份计，其原辅料包括：β-烟酰胺单核苷酸650份，磷脂酰丝氨酸150份，红景天提取物220份，西洋参提取物155份，淀粉200份、甘露醇100份、微粉硅胶55份、交联聚维酮100份、乳糖150份、微晶纤维素200份、硬脂酸镁20份。
10.权利要求6至9中任一项所述保健食品的制备方法，其特征在于，将权利要求1至4中任一项组合物和食品学上可接受的辅料混合，然后进行剂型的制备。
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202210589588.3A CN115137072A (zh) | 2022-05-27 | 2022-05-27 | 一种增强免疫的组合物及其制备方法 |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202210589588.3A CN115137072A (zh) | 2022-05-27 | 2022-05-27 | 一种增强免疫的组合物及其制备方法 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN115137072A true CN115137072A (zh) | 2022-10-04 |
Family
ID=83407221
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN202210589588.3A Pending CN115137072A (zh) | 2022-05-27 | 2022-05-27 | 一种增强免疫的组合物及其制备方法 |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN115137072A (zh) |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN116236499A (zh) * | 2022-12-13 | 2023-06-09 | 泓博元生命科技（深圳）有限公司 | 预防和治疗炎症因子风暴的组合物 |
Citations (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN103315299A (zh) * | 2013-07-08 | 2013-09-25 | 北京东方红航天生物技术股份有限公司 | 一种具有增强免疫力和记忆力功能的保健食品 |
| CN105876415A (zh) * | 2014-11-04 | 2016-08-24 | 威海特伦斯生物工程有限公司 | 一种具有增强免疫力的玛咖制剂及其制备方法 |
| CN113209166A (zh) * | 2021-05-28 | 2021-08-06 | 成都健腾生物技术有限公司 | 一种含烟酰胺单核苷酸的抗衰老中药组合物及其制备方法 |
-
2022
- 2022-05-27 CN CN202210589588.3A patent/CN115137072A/zh active Pending
Patent Citations (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN103315299A (zh) * | 2013-07-08 | 2013-09-25 | 北京东方红航天生物技术股份有限公司 | 一种具有增强免疫力和记忆力功能的保健食品 |
| CN105876415A (zh) * | 2014-11-04 | 2016-08-24 | 威海特伦斯生物工程有限公司 | 一种具有增强免疫力的玛咖制剂及其制备方法 |
| CN113209166A (zh) * | 2021-05-28 | 2021-08-06 | 成都健腾生物技术有限公司 | 一种含烟酰胺单核苷酸的抗衰老中药组合物及其制备方法 |
Cited By (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN116236499A (zh) * | 2022-12-13 | 2023-06-09 | 泓博元生命科技（深圳）有限公司 | 预防和治疗炎症因子风暴的组合物 |
| CN116236499B (zh) * | 2022-12-13 | 2024-03-22 | 泓博元生命科技（深圳）有限公司 | 预防和治疗炎症因子风暴的组合物 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| WO2010109961A1 (ja) | アルクチゲニン高含有ゴボウシエキス及びその製造方法 | |
| CN100423727C (zh) | 一种抗肿瘤的药物组合物及其制备工艺 | |
| CN109602756A (zh) | 一种解酒组合物及其制备方法与应用 | |
| CN115137072A (zh) | 一种增强免疫的组合物及其制备方法 | |
| CN101033245A (zh) | 具栖冬青苷的制备方法及应用 | |
| CN101049301A (zh) | 一种抗痛风的双黄酮类化合物药物制剂 | |
| CN109453267A (zh) | 解酒组合物及其制备方法与应用 | |
| CN101032532A (zh) | 一种含有从桑黄中提取的活性物质的药物组合物、制备方法及其在制备药物中的应用 | |
| CN1376397A (zh) | 灵芝茶及其制作方法 | |
| CN107537028B (zh) | 一种同时辅助降血糖及降血压的配方及其制备方法 | |
| CN109432181A (zh) | 缓解抑郁症的组合物及其制备方法与应用 | |
| CN102258570B (zh) | 具有抑制α-葡萄糖苷酶活性的组合物及其制备方法 | |
| CN1150917C (zh) | 大花红景天有效成份制剂及制备方法 | |
| CN101081227B (zh) | 甘草酸二铵的组合物 | |
| CN105687218A (zh) | 格列吡嗪/阿卡波糖降糖口服制剂组合物及其制备方法 | |
| CN1839863A (zh) | 一种治疗糖尿病的药物组合物及其制备方法和用途 | |
| CN109620863A (zh) | 一种缓解抑郁症的组合物及其制备方法与应用 | |
| CN1543968A (zh) | 用桑白皮提取物制备的药物制剂 | |
| CN109223826A (zh) | 一种复方维生素钙片剂 | |
| CN1223371C (zh) | 大花红景天有效成份制剂及制备方法 | |
| CN104082742B (zh) | 一种调理血糖平衡的功能性食品 | |
| CN108721340A (zh) | 一种单方中药制剂及其制备方法和应用 | |
| CN1304018C (zh) | 菊花止咳清咽制剂 | |
| CN1785416A (zh) | 治疗胆石症的药物制剂及其制备方法 | |
| CN1911410A (zh) | 一种治疗肺结核的药物及其制备方法 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination |